On March 9, 2026, Citizens initiated coverage of Immix Biopharma (NasdaqCM:IMMX) with a Market Outperform recommendation. The average one-year price target for Immix Biopharma is set at $13.26 per share, indicating a potential upside of 30.83% from its current closing price of $10.14 per share. The targets range from a low of $12.12 to a high of $14.70.
As of February 25, 2026, Immix Biopharma’s projected annual revenue stands at $12 million, with a non-GAAP EPS forecast of -$0.87. Institutional interest has surged, with 68 funds owning shares, a 58.14% increase in just the last quarter. Total institutional ownership has grown by 710.97% to 24,393,000 shares, reflecting an average portfolio weight of 0.13%, up by 347.49%.
Janus Henderson Group holds the largest stake at 7.44% with 3,922,000 shares, followed by Saturn V Capital Management with 5.69% ownership via 2,999,000 shares. Other notable shareholders include Eventide Asset Management and Marshall Wace, Llp, with significant increases in their holdings in the past quarter.
